DS
ABUS icon

David Shaw’s Arbutus Biopharma ABUS Stock Holding History

David Shaw’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Buy
381,863
+238,662
+167% +$1.05M ﹤0.01% 3272
2026
Q1 		$644K Sell
143,201
-88,562
-38% -$387K ﹤0.01% 3717
2025
Q4 		$1.11M Buy
231,763
+41,811
+22% +$188K ﹤0.01% 3463
2025
Q3 		$862K Buy
189,952
+149,252
+367% +$548K ﹤0.01% 3547
2025
Q2 		$126K Buy
+40,700
New +$135K ﹤0.01% 4107
2022
Q2 		– Sell
-19,698
Closed -$59K – 5293
2022
Q1 		$59K Sell
19,698
-3,202
-14% -$9.8K ﹤0.01% 5106
2021
Q4 		$89K Buy
+22,900
New +$89K ﹤0.01% 5089
2019
Q3 		– Sell
-19,300
Closed -$40K – 3769
2019
Q2 		$40K Sell
19,300
-28,747
-60% -$73.5K ﹤0.01% 3598
2019
Q1 		$172K Hold
48,047
– – ﹤0.01% 3423
2018
Q4 		$184K Sell
48,047
-12,509
-21% -$61.6K ﹤0.01% 3564
2018
Q3 		$572K Sell
60,556
-409,952
-87% -$4.07M ﹤0.01% 3030
2018
Q2 		$3.44M Sell
470,508
-239,954
-34% -$1.43M ﹤0.01% 1807
2018
Q1 		$3.55M Sell
710,462
-495,663
-41% -$2.62M ﹤0.01% 1643
2017
Q4 		$6.09M Sell
1,206,125
-547,980
-31% -$3.21M 0.01% 1358
2017
Q3 		$10.9M Buy
1,754,105
+19,576
+1% +$83.7K 0.02% 895
2017
Q2 		$6.24M Sell
1,734,529
-12,573
-0.7% -$43.3K 0.01% 1184
2017
Q1 		$5.68M Buy
1,747,102
+12,499
+0.7% +$34.7K 0.01% 1205
2016
Q4 		$4.25M Buy
1,734,603
+13,622
+0.8% +$39.6K 0.01% 1455
2016
Q3 		$5.92M Sell
1,720,981
-20,914
-1% -$81.7K 0.01% 1189
2016
Q2 		$6.06M Buy
1,741,895
+30,326
+2% +$128K 0.01% 1165
2016
Q1 		$7.07M Sell
1,711,569
-159,891
-9% -$571K 0.01% 1057
2015
Q4 		$8.33M Buy
1,871,460
+14,384
+0.8% +$78.8K 0.01% 1056
2015
Q3 		$11.3M Sell
1,857,076
-157,536
-8% -$1.4M 0.02% 894
2015
Q2 		$23.9M Buy
2,014,612
+332,712
+20% +$5.06M 0.04% 567
2015
Q1 		$29.4M Buy
1,681,900
+1,625,221
+2,867% +$33.3M 0.05% 468
2014
Q4 		$859K Buy
56,679
+45,773
+420% +$790K ﹤0.01% 2946
2014
Q3 		$231K Buy
+10,906
New +$178K ﹤0.01% 3822

Other funds holding ABUS

California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's ABUS Position: Q2 2026 in Review

David Shaw increased its Arbutus Biopharma (ABUS) stake by 167% in Q2 2026, buying an estimated $1.05M and bringing the position to 381,863 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

David Shaw first reported a position in ABUS in Q3 2014 and has held it in 27 quarters since. The position peaked at $29.4M in Q1 2015. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • David Shaw held 381,863 shares of Arbutus Biopharma worth $1.83M as of Q2 2026.
  • David Shaw bought 238,662 Arbutus Biopharma shares in Q2 2026, an estimated $1.05M.
  • Arbutus Biopharma made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3272 holding.
  • David Shaw first reported a position in Arbutus Biopharma in Q3 2014 and has held it in 27 quarters since.
  • David Shaw's Arbutus Biopharma position peaked at $29.4M in Q1 2015.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.